Literature DB >> 21417949

Hyponatremia, hypochloremia, and hypoalbuminemia predict an increased risk of mortality during the first year of antiretroviral therapy among HIV-infected Zambian and Kenyan women.

Christine N Dao1, Philip J Peters, James N Kiarie, Isaac Zulu, Peter Muiruri, John Ong'ech, Winfred Mutsotso, Dara Potter, Lungowe Njobvu, Jeffrey S A Stringer, Craig B Borkowf, Omotayo Bolu, Paul J Weidle.   

Abstract

Early mortality rates after initiating antiretroviral therapy (ART) are high in sub-Saharan Africa. We examined whether serum chemistries at ART initiation predicted mortality among HIV-infected women. From May 2005 to January 2007, we enrolled women initiating ART in a prospective cohort study in Zambia and Kenya. We used Cox proportional hazards models to identify risk factors associated with mortality. Among 661 HIV-infected women, 53 (8%) died during the first year of ART, and tuberculosis was the most common cause of death (32%). Women were more likely to die if they were both hyponatremic (sodium <135 mmol/liter) and hypochloremic (chloride <95 mmol/liter) (37% vs. 6%) or hypoalbuminemic (albumin <34 g/liter, 13% vs. 4%) when initiating ART. A body mass index <18 kg/m(2) [adjusted hazard ratio (aHR) 5.3, 95% confidence interval (CI) 2.6-10.6] and hyponatremia with hypochloremia (aHR 4.5, 95% CI 2.2-9.4) were associated with 1-year mortality after adjusting for country, CD4 cell count, WHO clinical stage, hemoglobin, and albumin. Among women with a CD4 cell count >50 cells/μl, hypoalbuminemia was also a significant predictor of mortality (aHR=3.7, 95% CI 1.4-9.8). Baseline hyponatremia with hypochloremia and hypoalbuminemia predicted mortality in the first year of initiating ART, and these abnormalities might reflect opportunistic infections (e.g., tuberculosis) or advanced HIV disease. Assessment of serum sodium, chloride, and albumin can identify HIV-infected patients at highest risk for mortality who may benefit from more intensive medical management during the first year of ART.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21417949     DOI: 10.1089/AID.2010.0345

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  20 in total

1.  Commentary on: Serum Albumin for Tuberculosis in HIV Infected Patients Eligible for Antiretroviral Therapy.

Authors:  Viroj Wiwanitkit
Journal:  Bioimpacts       Date:  2013-12-02

2.  Sustained Effect of a Community-based Behavioral and Nutrition Intervention on HIV-related Outcomes Among Women Living With HIV in Rural India: A Quasi-experimental Trial.

Authors:  Adeline M Nyamathi; Sanghyuk S Shin; Sanjeev Sinha; Catherine L Carpenter; Dana Rose Garfin; Padma Ramakrishnan; Kartik Yadav; Maria L Ekstrand
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-01       Impact factor: 3.731

3.  Electrolyte imbalance and sleep problems during anti-retroviral therapy: an under-recognized problem.

Authors:  Md Dilshad Manzar; Peter Sony; Mohammed Salahuddin; Abera Kumalo; Mathewos Geneto; Seithikurippu R Pandi-Perumal; Adam Moscovitch; Ahmed S BaHammam
Journal:  Sleep Sci       Date:  2017 Apr-Jun

Review 4.  Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients.

Authors:  Carlos G Musso; Waldo H Belloso; Richard J Glassock
Journal:  World J Nephrol       Date:  2016-01-06

5.  Association of serum albumin concentration with mortality, morbidity, CD4 T-cell reconstitution among tanzanians initiating antiretroviral therapy.

Authors:  Christopher R Sudfeld; Sheila Isanaka; Said Aboud; Ferdinand M Mugusi; Molin Wang; Guerino E Chalamilla; Wafaie W Fawzi
Journal:  J Infect Dis       Date:  2013-01-14       Impact factor: 5.226

6.  Serum albumin and short-term risk for mortality and cardiovascular disease among HIV-infected veterans.

Authors:  Joshua Lang; Rebecca Scherzer; Cristin C Weekley; Phyllis C Tien; Carl Grunfeld; Michael G Shlipak
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

7.  Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection.

Authors:  Rebecca Scherzer; Steven B Heymsfield; David Rimland; William G Powderly; Phyllis C Tien; Peter Bacchetti; Michael G Shlipak; Carl Grunfeld
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

8.  Serum albumin and kidney function decline in HIV-infected women.

Authors:  Joshua Lang; Rebecca Scherzer; Phyllis C Tien; Chirag R Parikh; Kathryn Anastos; Michelle M Estrella; Alison G Abraham; Anjali Sharma; Mardge H Cohen; Anthony W Butch; Marek Nowicki; Carl Grunfeld; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2014-07-22       Impact factor: 8.860

9.  Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study.

Authors:  Andreas Ronit; Shweta Sharma; Jason V Baker; Rosie Mngqibisa; Tristan Delory; Luis Caldeira; Nicaise Ndembi; Jens D Lundgren; Andrew N Phillips
Journal:  J Infect Dis       Date:  2018-01-17       Impact factor: 5.226

10.  Diagnostic and Prognostic Value of Serum Albumin for Tuberculosis in HIV Infected Patients Eligible for Antiretroviral Therapy: Datafrom an HIV Cohort Study in India.

Authors:  Gerardo Alvarez-Uria; Manoranjan Midde; Raghavakalyan Pakam; Praveen Kumar Naik
Journal:  Bioimpacts       Date:  2013-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.